What happened
Australia's TGA updated warnings for products with GLP-1 activity following reports of non-arteritic anterior ischaemic optic neuropathy, a rare and potentially serious eye disorder.
What we know
The regulator says sudden vision loss requires urgent medical attention. The update covers products marketed in Australia and follows regulatory assessment of available signals and data.
What we do not know
A class warning cannot predict an individual's risk or establish causation in every reported case. Labels and regulatory decisions may differ between jurisdictions.
Why it matters
This is safety information to contextualise, not amplify into a general alarm. Nobody should stop or change prescribed treatment solely because of a news report.